XNAS · Healthcare · Biotechnology
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -1.19 | -1.17 | +1.68% | $0 | ✅ Beat | +0.00% | +0.00% | -7.63% |
| 2026-02-26 | Q4 2025 | -1.20 | -1.31 | -9.17% | $0 | ❌ Miss | -2.38% | -6.39% | +21.28% |
| 2025-11-03 |
| Q3 2025 |
| -1.16 |
| -1.15 |
| +0.86% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -1.00 | -1.07 | -7.00% | $0 | ❌ Miss | +5.54% | +10.88% | +8.80% |
| 2025-02-27 | Q4 2024 | -0.84 | -0.84 | +0.00% | $0 | ➖ Inline | -3.37% | -2.69% | -12.43% |
| 2024-11-12 | Q3 2024 | -0.81 | -0.81 | +0.00% | $0 | ➖ Inline | -3.27% | -10.46% | -9.08% |
| 2024-02-29 | Q4 2023 | -0.76 | -0.64 | +15.79% | $0 | ✅ Beat | — | — | — |
| 2023-11-08 | Q3 2023 | -0.77 | -0.73 | +5.19% | $0 | ✅ Beat | -6.69% | -9.33% | +19.25% |
Showing last 8 quarters.